depression
Recent studies challenge Kennedy’s claims about vaccines, Tylenol and antidepressants
They’re prominent talking points for Health Secretary Robert F. Kennedy Jr.
Recent studies challenge Kennedy's claims about vaccines, Tylenol and antidepressants
They’re prominent talking points for Health Secretary Robert F. Kennedy Jr. and his top officials: Taking Tylenol while pregnant could be linked to autism. Antidepressants may be harmful during pregnancy. Aluminum salts in vaccines might pose a health risk. And Covid shots don’t benefit healthy kids. The remarks have sowed confusion over the past year, as scientists warn there isn’t evidence to back them up. Nevertheless, federal health agencies have pursued policies based on the assertions.Now,
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
LONDON & NEW YORK--(BUSINESS WIRE)--Feb 24, 2026--
Research suggests physical activity can reduce depressive symptoms.
A large review adds weight to an old idea: movement can help ease depression. Here’s how to think about exercise as part of treatment and recovery.
Advanced TMS Protocol Demonstrates Increased Remission Rates In Depression
(MENAFN - PR Newswire) Key findings at a glance: A recent study evaluated 600 adults with depression. Over 80% of participants experienced significant symptom improvement with a novel ...
Single dose of powerful psychedelic cuts depression symptoms in clinical study
Breakthrough study finds single dose of psychedelics significantly reduced depression symptoms in clinical trial, with effects lasting up to six months.
Postpartum depression in dads is common – we can now spot and treat it
Fathers may get postpartum depression at a similar rate to mothers, but it’s often overlooked. At last, the way we diagnose and treat it is improving, for the good of the whole family
Magnus Medical Moves to Protect Intellectual Property Behind Breakthrough SAINT Accelerated Depression Therapy
BURLINGAME, Calif.--(BUSINESS WIRE)--Feb 18, 2026--
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
LONDON & NEW YORK--(BUSINESS WIRE)--Feb 17, 2026--
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has completed an in-person Type C guidance meeting at the headquarters of the US Food and Drug Administration. The meeting was attended by leaders of the FDA Division of Psychiatry Products, the FDA Office of Neuroscience, and the FDA Center for Drug Evaluation and Research.
Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting For NRX-100 NDA Pathway
(MENAFN - Investor Brand Network)NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S. Food and Drug Administration, attended by leadership ...
Instanosis Xylazine Rapid Test (Urine) Granted FDA Breakthrough Device Designation
PHILADELPHIA--(BUSINESS WIRE)--Feb 17, 2026--